CT Cadrenal Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Cadrenal Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €6.7m. The latest transaction was disclosed on 1 July 2026 (Cession). Among the most active insiders: Pham Quang X. All data is openly available.
€400,013
37 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Cadrenal Therapeutics, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$14.00.
Buys €81,631 €400,013 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2026
All Executives49 Thresholds0 Prospectus0 Other0
Declarations 49 total
▼ Chairman and CEO · Executives · 29 Jun 2026
7,400 shares Common Stock SEC:0001213900-26-074557:0
▼ Chairman, CEO and Interim CFO · Executives · 25 Jun 2026
2,127 shares Common Stock SEC:0001213900-26-072789:0
▼ Chairman, CEO and Interim CFO · Executives · 26 Jun 2026
9,029 shares Common Stock SEC:0001213900-26-072789:1
▼ Chairman, CEO and Interim CFO · Executives · 22 Jun 2026
9,167 shares Common Stock SEC:0001213900-26-071578:0
▼ Chairman, CEO and Interim CFO · Executives · 23 Jun 2026
2,277 shares Common Stock SEC:0001213900-26-071578:1
▼ Chairman, CEO and Interim CFO · Executives · 16 Jun 2026
3,613 shares Common Stock SEC:0001213900-26-070248:0
▼ Chairman, CEO and Interim CFO · Executives · 17 Jun 2026
513 shares Common Stock SEC:0001213900-26-070248:1
● Officer · Executives · 15 Jun 2026
40,000 shares @ US$3.71 1.64% mcap 100.0% of flow Common SEC144:0001628280-26-043385
▼ Chairman, CEO and Interim CFO · Executives · 11 Jun 2026
1,462 shares Common Stock SEC:0001213900-26-068981:0
▼ Chairman, CEO and Interim CFO · Executives · 12 Jun 2026
12,996 shares Common Stock SEC:0001213900-26-068981:1
▼ Chairman, CEO and Interim CFO · Executives · 15 Jun 2026
3,666 shares Common Stock SEC:0001213900-26-068981:2
▼ Chairman, CEO and Interim CFO · Executives · 8 Jun 2026
5,893 shares Common Stock SEC:0001213900-26-067484:0
▼ Chairman, CEO and Interim CFO · Executives · 9 Jun 2026
12,992 shares Common Stock SEC:0001213900-26-067484:1
▼ Chairman, CEO and Interim CFO · Executives · 10 Jun 2026
3,500 shares Common Stock SEC:0001213900-26-067484:2
▼ CEO and Chairman · Executives · 3 Jun 2026
2,323 shares @ US$4.26 0.097% mcap 4.3% of flow Common Stock SEC:0001213900-26-065925:0
▼ CEO and Chairman · Executives · 4 Jun 2026
3,898 shares @ US$4.41 0.17% mcap 7.4% of flow Common Stock SEC:0001213900-26-065925:1
▼ CEO and Chairman · Executives · 5 Jun 2026
2,064 shares @ US$4.42 0.089% mcap 3.9% of flow Common Stock SEC:0001213900-26-065925:2
▼ CEO and Chairman · Executives · 29 May 2026
303 shares @ US$5.01 0.8% of flow Common Stock SEC:0001213900-26-064357:0
▼ CEO and Chairman · Executives · 2 Jun 2026
349 shares @ US$4.46 0.8% of flow Common Stock SEC:0001213900-26-064357:1
▼ CEO and Chairman · Executives · 11 May 2026
6,476 shares @ US$5.76 18.9% of flow Common Stock SEC:0001213900-26-062862:0
▼ CEO and Chairman · Executives · 12 May 2026
3,298 shares @ US$5.28 8.8% of flow Common Stock SEC:0001213900-26-062862:1
▼ CEO and Chairman · Executives · 28 May 2026
2,989 shares @ US$4.93 7.6% of flow Common Stock SEC:0001213900-26-062862:2
▼ CEO and Chairman · Executives · 22 May 2026
1,165 shares @ US$5.69 3.4% of flow Common Stock SEC:0001213900-26-061167:0
▼ Chief Financial Officer · Executives · 29 Dec 2025
9,933 shares @ US$6.97 36.3% of flow Common Stock SEC:0001213900-25-127110:0
▼ CEO and Chairman · Executives · 27 Oct 2025
1,315 shares @ US$13.99 9.4% of flow Common Stock SEC:0001213900-25-103146:1
25 of 49 declarations
Load more (24 remaining) Acerca de Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. es una empresa centrada en el desarrollo de tratamientos para enfermedades renales. Cotiza en NASDAQ bajo el ticker CDNL.